---
figid: PMC9085242__aging-14-204031-g001
pmcid: PMC9085242
image_filename: aging-14-204031-g001.jpg
figure_link: /pmc/articles/PMC9085242/figure/f1/
number: Figure 1
figure_title: ''
caption: The MEK inhibitor trametinib suppresses KRAS mutant pancreatic cancer cells.
  (A) The structure of the MEK inhibitor trametinib. (B) Fitting curve of cytostatic
  responses illustrated a decreasing concentration gradient of trametinib in 7 KRAS
  mutant pancreatic cancer cell lines (AsPC-1, MIA PaCa-2, PANC-1, HuP-T4, HuP-T3,
  PSN1, and CFPAC-1).
article_title: Synergistic blocking of RAS downstream signaling and epigenetic pathway
  in KRAS mutant pancreatic cancer.
citation: Xiaofei Zhang, et al. Aging (Albany NY). 2022 Apr 30;14(8):3597-3606.
year: '2022'

doi: 10.18632/aging.204031
journal_title: Aging (Albany NY)
journal_nlm_ta: Aging (Albany NY)
publisher_name: Impact Journals

keywords:
- pancreatic ductal adenocarcinoma
- MEK inhibitor
- BET inhibitor
- synergistic effect
- autophagy

---
